Logo

Pfizer's Bavencio (avelumab) + Axitinib Dual Regimen Receive EC's Approval as 1L Treatment for Advanced Renal Cell Carcinoma

Share this

Pfizer's Bavencio (avelumab) + Axitinib Dual Regimen Receive EC's Approval as 1L Treatment for Advanced Renal Cell Carcinoma

Shots:

  • The approval is based in P-III JAVELIN Renal 101 study assessing Bavencio + Axitinib vs Sunitinib in 886 patients with untreated advanced or metastatic RCC with all IMDC prognostic risk groups and irrespective of PD-L1 expression
  • The P-III JAVELIN Renal 101 study resulted in improvement in PFS (13.3 vs 8.0 mos.) with a median follow-up for OS is 19mos. The EC’s approval follows the FDA’s approval of Bavencio + Axitinib for 1L treatment of advanced RCC in May’2019
  • Bavencio is an anti-PD-L1 antibody- act by blocking the interaction of PD-L1 with PD-1 receptors- demonstrating T cell-mediated antitumor immune response suppression in preclinical models. In Nov’2014- Merck KGaA & Pfizer collaborated to co-develop & co-commercialize Bavencio

Click here to­ read full press release/ article | Ref: Pfizer | Image: The Times


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions